Anti-PD-1 antibodies for the treatment of B-cell lymphoma Importance of PD-1(+) T-cell subsets

作者：Chu Fuliang; Neelapu Sattva S^*

来源：OncoImmunology, 2014, 3(2): e28101.

DOI：10.4161/onci.28101

• PD-1
• clinical trial
• T cell
• rituximab
• lymphoma

Monoclonal antibodies specific for programmed cell death 1 (PDCD1, best known as PD-1) have been shown to mediate antineoplastic effects in follicular lymphoma patients. However, the relative proportion of intratumoral PD-1(+) T-cell subsets, in particular follicular helper T cells (which exert pro-tumor functions) and effector T cells (which have anticancer activity), may impact clinical outcome, and should therefore be carefully considered for patient selection in this setting.

• 出版日期2014-2